Strides Pharma Science’s board approves incremental investments in Stelis
20th Sep 2019

Strides Pharma Science’s board has approved an additional investment up to a maximum of $40 million over a period of 24 months for a controlling stake in Stelis Biopharma (Stelis).

The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides’ re-entry into sterile injectables business post the completion of the company’s non-compete period in December 2019.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.